InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
+7.5%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Valentine Keith, Chief Executive Officer. Director active across 4 companies, notably SI-BONE, Inc.. Cumulatively, 19 disclosures have been logged. Split: 1 buy · 0 sell. Total volume traded: €237k. Activity tracked since 10 June 2021. The latest transaction was filed on 2 August 2024 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations19 total
32,012 sharesCommon StockSEC:0001289408-26-000004:0
39,000 shares@ US$6.55100.0% of flowCommon StockSEC:0001415889-24-020722:0
Ideal exit: 29 Apr 2025 (T+270)
15,077 shares0Common StockSEC:0001415889-24-020473:0
4,866 shares0Common StockSEC:0001562180-23-005114:0
16,290 shares@ US$20.6073.6% of flowCommon StockSEC:0001209191-23-014687:0
5,824 shares@ US$21.2226.4% of flowCommon StockSEC:0001209191-23-006009:0
140,515 shares0Common StockSEC:0001209191-23-002642:0
333,797 sharesCommon StockSEC:0001637761-23-000031:0
12,183 sharesCommon StockSEC:0001637761-23-000008:0
2,385 shares@ US$4.8023.0% of flowCommon StockSEC:0001637761-22-000107:0
8,324 shares0Common StockSEC:0001562180-22-005235:0
26,196 sharesCommon StockSEC:0001637761-22-000025
26,196 sharesCommon StockSEC:0001637761-22-000025:0
1,026 shares@ US$8.9217.0% of flowCommon StockSEC:0001637761-22-000007
1,026 shares@ US$8.9217.0% of flowCommon StockSEC:0001637761-22-000007:0
1,356 shares@ US$8.9221.5% of flowCommon StockSEC:0001637761-21-000151:0
1,356 shares@ US$8.9221.5% of flowCommon StockSEC:0001637761-21-000151
3,848 shares0Common StockSEC:0001562180-21-004256
3,848 shares0Common StockSEC:0001562180-21-004256:0
19 of 19 declarations
About Valentine Keith
Keith Valentine is Chief Executive Officer at SI-BONE, Inc. and SeaSpine Holdings Corp. He oversees the operations of both companies and is responsible for implementing the business strategy. His experience in the medical sector enables him to effectively lead growth initiatives.
